FLT3 and acute myeloid leukemia: This suggests that increased JAK/STAT signaling is at least one mechanism by which FLT3-ITD cells may confer an oncogenic advantage over FLT3-TKD mutant activated cells; indeed, JAK inhibitors have been shown to elicit synergistic cell death in combination with FLT3 inhibition in FLT3-ITD AML cells in vitro [113].